Physician profile
Mark Pippenger
NPI 1235248246
$109,273.66
in general payments reported to CMS, 2019-2025
14 companies · $57K in 2025
The $57K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $116 · 2021: $370 · 2022: $48.25 · 2023: $166 · 2024: $51K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $30K · Travel and Lodging: $3,417 · Consulting Fee: $3,275 · Food and Beverage: $2,964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,000.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $29,910.00 |
| Travel and Lodging | $3,417.40 |
| Consulting Fee | $3,275.00 |
| Food and Beverage | $2,964.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73,283.02 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $34,956.39 | 2023-2025 | |
| Biogen, INC. | $534.67 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $172.46 | 2019 | |
| Life Molecular Imaging Ltd | $125.33 | 2024-2025 | Neuraceq |
| Neurocrine Biosciences, INC. | $40.53 | 2024-2025 | Ingrezza |
| Abiomed | $32.22 | 2024 | Impella |
| Viatris Specialty LLC | $24.48 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $19.41 | 2023 | Xarelto |
| Glaxosmithkline, LLC. | $18.59 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $18.04 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $17.78 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.84 | 2025 | Caplyta |
| Pfizer INC. | $13.90 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pippenger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.